Oncolytic mineralized bacteria as potent locally administered immunotherapeutics
© 2024. The Author(s), under exclusive licence to Springer Nature Limited..
Oncolytic bacteria can trigger innate immune activity. However, the antitumour efficacy of inactivated bacteria is poor, and attenuated live bacteria pose substantial safety risks. Here we show that intratumourally injected paraformaldehyde-fixed bacteria coated with manganese dioxide potently activate innate immune activity, modulate the immunosuppressive tumour microenvironment and trigger tumour-specific immune responses and abscopal antitumour responses. A single intratumoural administration of mineralized Salmonella typhimurium suppressed the growth of multiple types of subcutaneous and orthotopic tumours in mice, rabbits and tree shrews and protected the cured animals against tumour rechallenge. We also show that mineralized bacteria can be administered via arterial embolization to treat orthotopic liver cancer in rabbits. Our findings support the further translational testing of oncolytic mineralized bacteria as potent and safe antitumour immunotherapeutics.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Nature biomedical engineering - (2024) vom: 21. März |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wang, Chenya [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 27.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1038/s41551-024-01191-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370043480 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370043480 | ||
| 003 | DE-627 | ||
| 005 | 20240328000255.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240323s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41551-024-01191-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1351.xml |
| 035 | |a (DE-627)NLM370043480 | ||
| 035 | |a (NLM)38514774 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wang, Chenya |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Oncolytic mineralized bacteria as potent locally administered immunotherapeutics |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 27.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer Nature Limited. | ||
| 520 | |a Oncolytic bacteria can trigger innate immune activity. However, the antitumour efficacy of inactivated bacteria is poor, and attenuated live bacteria pose substantial safety risks. Here we show that intratumourally injected paraformaldehyde-fixed bacteria coated with manganese dioxide potently activate innate immune activity, modulate the immunosuppressive tumour microenvironment and trigger tumour-specific immune responses and abscopal antitumour responses. A single intratumoural administration of mineralized Salmonella typhimurium suppressed the growth of multiple types of subcutaneous and orthotopic tumours in mice, rabbits and tree shrews and protected the cured animals against tumour rechallenge. We also show that mineralized bacteria can be administered via arterial embolization to treat orthotopic liver cancer in rabbits. Our findings support the further translational testing of oncolytic mineralized bacteria as potent and safe antitumour immunotherapeutics | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Zhong, Liping |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Jiachen |e verfasserin |4 aut | |
| 700 | 1 | |a Zhuang, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Gong, Fei |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xiaojing |e verfasserin |4 aut | |
| 700 | 1 | |a Tao, Huiquan |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Cong |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Fuquan |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Nailin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Junyan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Xinjun |e verfasserin |4 aut | |
| 700 | 1 | |a Huo, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Qian |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Yongxiang |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Rui |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Zhuang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature biomedical engineering |d 2016 |g (2024) vom: 21. März |w (DE-627)NLM271447966 |x 2157-846X |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:21 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41551-024-01191-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 21 |c 03 | ||